Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens.

Background: The spread of type I allergic diseases has reached epidemic dimensions. The success of therapeutic intervention is limited, and hence prophylactic vaccination is now seriously considered. However, immunization of healthy individuals requires safety standards far beyond those applicable for therapeutic approaches.